KSB 301

Drug Profile

KSB 301

Alternative Names: CB 2431; KSB301

Latest Information Update: 07 Dec 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator KS Biomedix Holdings
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Monoamine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Osteoarthritis

Most Recent Events

  • 07 Dec 2001 Discontinued-II for Osteoarthritis in European Union (PO)
  • 24 May 2001 KSB 301 is available for licensing (http://www.ksbiomedix.com/)
  • 23 May 2001 A phase IIb trial has commenced
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top